Skip to main content

Table 2 Ongoing study using “add-on” strategy with PDGF/PDGFR inhibitors in solid tumors

From: PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy

Regimen Mechanism of partner Diagnosis Phase Study design Start date Recruitment ClinicalTrials.gov Identifier
Imatinib+
 Pemetrexed Cytotoxic drugs Pleural mesothelioma 2 Single group, open label 11/2014 Active, not recruiting NCT02303899
 Temzolomide Cytotoxic drugs Melanoma 1/2 Single group, open label 01/2003 Active, not recruiting NCT00667953
 Regoragenib Multi-targeted TKI GIST 2 Randomized, open label 02/2015 Recruiting NCT02365441
 BYL719 PI3K inhibitor GIST 1 Single group, open label 02/2013 Active, not recruiting NCT01735968
 Pembrolizumab Check point inhibitor Melanoma 1/2 Single group, open label 11/2016 Recruiting NCT02812693
 Letrozole Antihormonal drug Breast cancer 2 Single group, open label 10/2003 Active, not recruiting NCT00338728
 Binimetinib MEK inhibitor GIST 1b/2 Single group, open label 11/2013 Recruiting NCT01991379
 BGJ398 FGFR inhibitor GIST 1b/2 Single group, open label 10/2014 Active, not recruiting NCT02257541
 Ipilimumab Check point inhibitor Cancer 1 Single group, open label 02/2013 Recruiting NCT01738139
Olaratumab+
 Paclitaxel/carboplatin Cytotoxic drugs NSCLC 2 Randomized, open label 01/2010 Active, not recruiting NCT00918203
 Nab-paclitaxel/gemcitabine Cytotoxic drugs Pancreatic cancer 1b/2 Randomized, double-blind 01/2017 Recruiting NCT03086369
 ADM Cytotoxic drugs STS 3 Randomized, double-blind 09/2015 Active, not recruiting NCT02451943
 Standard chemos Cytotoxic drugs Pediatric cancer 1 Non-randomized, open label 08/2016 Recruiting NCT02677116
 ADM Cytotoxic drugs STS 2 Non-randomized, open label 02/2016 Recruiting NCT02584309
 Gemcitabine/ADM Cytotoxic drugs STS 1b/2 Randomized, double-blind 03/2016 Recruiting NCT02659020
 Trabectedin/ADM Cytotoxic drugs Leiomyosarcoma 1 Non-randomized, open label Not yet Not yet recruiting NCT03437070
 ADM Cytotoxic drugs STS 1 Single group, open label 10/2016 Active, not recruiting NCT02783599
 ADM Cytotoxic drugs Cancer 1 Non-randomized, open label 03/2016 Active, not recruiting NCT02377752
 ADM/ifosfamide Cytotoxic drugs STS 1 Single group, open label 10/2017 Recruiting NCT03283696
 Pembrolizumab Check point inhibitor STS 1 Non-randomized, open label 07/2017 Recruiting NCT03126591
  1. PI3K phosphatidylinositol 3-kinase, STS soft tissue sarcoma, ADM adriamycin